The deal concerns the extension of joint research and development activity, common programs for treating and diagnosing patients, and studies of diseases such as diabetes, chronic kidney disease, and cardiac failure.
AstraZeneca has already cooperated with the university in almost two-thirds of its clinical trials but the percentage could exceed 80% due to the new partnership, the parties said.
Béla Merkely, the university's rector, said the results of the joint work are expected to be utilized in patient care.
AstraZeneca spends HUF 2 billion a year on R&D activity in Hungary. AstraZeneca Kereskedelmi és Szolgáltató had revenue of more than HUF 15 bln in 2020, including export sales of HUF 2.5 bln.



